Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Expert Shares Intriguing Ovarian Cancer Cases, Highlights Individualized Treatment

May 11th 2018

Matthew Borst, MD, highlights the need for neoadjuvant therapy versus upfront surgery in newly diagnosed patients, effective treatment management for recurrent platinum-sensitive disease, and what to do in the third-line setting and beyond.

Frontline Treatment in Ovarian Cancer Could Undergo Transformation

May 10th 2018

Heather Dalton, MD, discusses the developing standard of care for the frontline treatment of patients with ovarian cancer.

Dr. Essel Discusses Long-Term Bevacizumab in Ovarian Cancer

May 9th 2018

Kathleen Essel, MD, fellow, University of Oklahoma Health Science Center, discusses a study on the effects of long-term bevacizumab (Avastin) use in patients with ovarian cancer.

Expert Encourages Widespread Use of ERAS in Ovarian Cancer

May 9th 2018

Snehal Bhoola, MD, discusses the implementation of enhanced recovery after surgery in ovarian cancer.

Olaparib Tablets Approved in Europe for Ovarian Cancer, Regardless of BRCA Status

May 9th 2018

The European Commission has approved olaparib tablets (Lynparza) as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian tube or primary peritoneal cancer.

Rucaparib FDA Approval Creates Trifecta of Maintenance PARP Inhibitors in Ovarian Cancer

May 8th 2018

Lyndsay Willmott, MD, discusses the use of PARP inhibitors in patients with ovarian cancer and details the mechanisms of resistance that have been identified so far.

Monk Highlights Clinical Trials in Recurrent Ovarian Cancer

May 7th 2018

Bradley J. Monk, MD, FACOG, FACS, discusses the promise of new therapies and regimens in patients with ovarian cancer in the recurrent setting.

Dr. Borst on Homologous Recombination Deficiency in Patients With Ovarian Cancer

May 5th 2018

Matthew Borst, MD, director, GYN/Oncology, Banner Good Samaritan Regional Medical Center, clinical assistant professor of medicine, University of Arizona, Arizona Oncology, discusses homologous recombination deficiency (HRD) in patients with ovarian cancer.

Dr. Dalton on Toxicities in the Frontline Treatment of Ovarian Cancer

April 27th 2018

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses toxicities in the frontline treatment of patients with ovarian cancer.

Managing Ovarian Cancer Patients in the Future

April 26th 2018

Therapy Selection in BRCA-Mutated Ovarian Cancer

April 26th 2018

Sequencing Therapies in Ovarian Cancer

April 26th 2018

PARP Inhibitor Selection in Ovarian Cancer

April 26th 2018

Additional Considerations: PARPs for EOC in Practice

April 26th 2018

PARP Inhibitors in Recurrent Ovarian Cancer

April 26th 2018

Secondary Debulking in Recurrent Ovarian Cancer

April 26th 2018

Bevacizumab in Recurrent Ovarian Cancer

April 26th 2018

Approaching Recurrent Ovarian Cancer

April 26th 2018

Biomarkers and Molecular Testing in Ovarian Cancer

April 26th 2018

I-O Therapy in Advanced Ovarian Cancer

April 26th 2018